Since the publication of the 2018 European Society of Cardiology/European Society of
Hypertension (ESC/ESH) Guidelines for the Management of Arterial Hypertension, several …

In the last 4 years, several evidence-based, national, and international guidelines on the
management of arterial hypertension have been published, mostly with concordant …

Arterial hypertension is the most prevalent modifiable risk factor associated with
cardiovascular morbidity and mortality. Although antihypertensive drugs are widely …

Background: The multicenter, international, randomized, blinded, sham-controlled
RADIANCE-HTN SOLO trial (A Study of the ReCor Medical Paradise System in Clinical …

Abstract This ESH Position Paper 2021 with updated proposed recommendations was
deemed necessary after the publication of a set of new pivotal sham-controlled randomized …

Background: Arterial hypertension is the most common comorbidity in patients with heart
failure with preserved ejection fraction (HFpEF) and mediates adverse hemodynamics …

Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the
widespread availability of both pharmacological and lifestyle therapeutic options, blood …

BACKGROUND: Renal denervation is a recognized adjunct therapy for hypertension with
clinically significant blood pressure (BP)-lowering effects. Long-term follow-up data are …

Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in
device-based hypertension therapies | European Heart Journal | Oxford Academic Skip to Main …

Objectives The aim of this multicenter, open-label trial was to evaluate the safety and
efficacy of alcohol-mediated renal denervation using a novel catheter system (the Peregrine …